Table I.
miR-29b expression and clinicopathological factors.
| miR-29b expression | |||
|---|---|---|---|
| Factors | Low (n=47), no. (%) | High (n=47), no. (%) | P-value |
| Age, mean years ± SD | 55±11 | 54±11 | |
| ER | |||
| Positive | 31 (66) | 32 (68) | 0.59 |
| Negative | 15 (32) | 12 (26) | |
| Progesterone receptor | |||
| Positive | 26 (55) | 31 (66) | 0.24 |
| Negative | 18 (38) | 13 (28) | |
| T factors | |||
| T1 | 13 (28) | 25 (53) | 0.01 |
| T2–4 | 34 (72) | 22 (47) | |
| Lymph node metastasis | |||
| Absent | 22 (47) | 27 (57) | 0.31 |
| Present | 25 (53) | 20 (43) | |
| Lymphatic invasion | |||
| Absent | 18 (38) | 16 (34) | 0.73 |
| Present | 23 (49) | 24 (51) | |
| Venous invasion | |||
| Absent | 33 (70) | 34 (72) | 0.60 |
| Present | 7 (15) | 6 (13) | |
| Stage | |||
| Stage I | 7 (15) | 17 (36) | 0.02 |
| Stages II–IV | 40 (85) | 30 (64) | |
miR-29b, microRNA-29b; SD; standard deviation, ER, estrogen receptor.